Recursion

About Recursion

Recursion is a pioneering company in AI-enabled drug discovery and development, focused on decoding biology to radically improve lives. Founded over a decade ago, their mission is to use AI to understand cellular disruptions driving disease and reduce the high failure rate of traditional drug discovery. They leverage vast datasets, automated labs, and supercomputing power to accelerate the development of first-in-class and best-in-class treatments for conditions with high unmet needs, such as aggressive cancers and rare diseases.

Products & Services

Recursion OS:A drug discovery and development platform that uses AI to identify new targets and design optimized molecules for potential treatments.

Pipeline of Treatments:An advanced pipeline of potential first-in-class and best-in-class treatments targeting oncology (e.g., advanced solid tumors, B-cell malignancies) and rare diseases (e.g., familial adenomatous polyposis, hypophosphatasia) across preclinical to Phase 3 stages.

LOWE:Recursion's LLM agent specifically designed for drug discovery to enhance research capabilities.

BioHive-2:One of the most powerful supercomputers in the pharmaceutical industry, built in collaboration with NVIDIA to process massive biological and chemical datasets.

Specialties

AI-enabled drug discovery High-throughput automated labs Biological and chemical data analysis Supercomputing for biopharma Oncology and rare disease treatments

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 200000000 MR: - FA: $200 million FAN: 200000000	D: 2024-06-26 FD: 2024-06-26	3 investors
2	RT: Underwritten Public Offering T: - FT: Underwritten Public Offering	A: 200000000 MR: - FA: $200.0 million FAN: 200000000	D: 2024-06-26 FD: 2024-06-26	3 investors
3	RT: PIPE T: - FT: PIPE	A: 50000000 MR: - FA: 50 million FAN: 50000000	D: 2023-07-12 FD: 2023-07-12	1 investors

Public Offering Latest

2024-06-26

$200.0M

3 investors (Pro only)

Underwritten Public Offering 2024-06-26

$200.0M

PIPE 2023-07-12

$50.0M

View 2 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

J

Jensen Huang

Founder and CEO of NVIDIA

J

Joerg Moeller

Member of the Executive Committee of Bayer AG's Pharmaceuticals Division and Head of Research and Development

J

James Sabry

Global Head of Pharma Partnering at Roche

C

Chris Gibson

Co-Founder and CEO

E

Erica Fox

Chief People and Impact Officer

D

David Hallett

Chief Scientific Officer

View 26 more team members with Pro

Unlock Full Team Directory

Recent News

Recursion Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised